Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of oral hypoglycemic agents for the treatment of T2DM that have a unique antidiabetic mechanism that inhibits the proximal renal tubule’s reabsorption of glucose and sodium, thus reducing the level of blood glucose3. Here, SLC5A2 is linked to type 2 diabetes mellitus.